Prior to the FDA approval of the liquid formulation of imatinib (Imkeldi), pediatric patients with cancer and those with dysphagia who required the medication faced several barriers to safely receiving the drug, according to Kate Gasparini, PharmD, BCOP, BCPPS.

“Whether or not a medication is available as a liquid formulation may seem trivial, but for those of us who work every day with this patient population, we know it makes all the difference,” Gasparini said in an interview with 

 “It can truly improve the quality of life for patients and their families to have a liquid formulation that’s easy to administer and readily available for a patient who has difficulty swallowing, especially for oral chemotherapy agents, which are essential in the treatment of certain pediatric [patients with] cancer. It’s one less thing for our patients and families to worry about when they’re undergoing these intensive treatments and, as the treating team, we know the patient will be able to get the therapy safely and reliably. It’s an additional peace of mind.”

Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York.

In November 2024, the FDA approved an oral solution of imatinib

 for the treatment of patients with certain forms of leukemia and other types of cancer.

 The agent was originally approved by the FDA in 2001 and is indicated for use in several cancer types including Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase, relapsed/refractory Ph-positive acute lymphoblastic leukemia (ALL), and myelodysplastic or myeloproliferative diseases associated with 

 It is also indicated for pediatric patients with Ph-positive CML in chronic phase and in combination with chemotherapy in newly diagnosed Ph-positive ALL.

In the interview, Gasparini discussed the challenges of administering oral therapies without a liquid formulation, the significance of the approval of the liquid solution of imatinib, and her role in counseling patients and families as they navigate treatment.

How is a clinical pharmacist’s role in the treatment of patients with cancer who are unable to swallow pills?

: I’m a clinical pharmacy specialist with 10 years of experience, specifically in pediatric oncology. In my current role, I rotate through inpatient service and 3 of our outpatient clinics. When I’m in the outpatient clinics, I conduct direct patient care visits. During those visits, I review medications, including chemotherapy agents, with patients and families, [and] I suggest modifications or adjustments to therapy in conjunction with the clinical team.

My role in the management of pediatric patients with cancer consists of a lot of supportive care and symptom management for patients [who are] actively receiving chemotherapy. In terms of treatment planning, I work very closely with the [clinical] team for patients starting new chemotherapy regimens or those requiring a modification in therapy to recommend appropriate dosing of various agents and supportive care medications. I [provide] education with patients and families on the administration of these medications in the home with adverse effect [AE] monitoring and counseling. I [also] assist the clinical team with medication procurement when necessary.

What are some of the challenges with administering oral treatments in pediatric patients or adult patients with difficulty swallowing?

The biggest challenge with administering treatments to patients who have difficulty swallowing, whether they are a young patient who hasn’t learned how to swallow pills or capsules yet, or our young adult patients with dysphagia, is whether the medications that the patients need are available in a liquid formulation. If there’s not a liquid formulation available, it is part of my role to help the team navigate whether the medications can be compounded into a liquid formulation for administration, or [if they can be] safely dissolved or manipulated by the patient or their families so that it can be given.

Depending on the medication, there could be established recipes for compounding or instructions on how to dissolve [it]. However, a lot of the time, there is some digging into the data and literature that is required to [determine] how to safely do this. Another barrier is identifying compounding pharmacies that patients can use to get medications made into a liquid formulation, if there is a compounding recipe available.

In the cases where we have patients or their families dissolve medications for administration at home, there’s a lot of education needed to do this safely. Depending on the medication, a lot of times they need to have supplies such as gowns, masks, gloves, medicine cups, syringes, pill crushers, and/or splitters. A lot goes into it.

This can be cumbersome for families. They might need to be educated several times. I’ve heard directly from caregivers and parents that they just want to do it correctly. I’ve had a dad say to me, ‘I just don’t want to mess this up.’ They just want to be able to administer it safely to their child.

What types of support do you provide for patients and their families for at-home formulations?

We have a lot of reminders and documentation that we give to patients on safely receiving oral chemotherapy at home. It can be overwhelming for families, so I always tell them that if they get home and forget what they’re doing, please call the clinic. I will go through this with a parent as many times as they need to feel safe in giving this to their child.

It can be very time consuming and cumbersome for patients and their families. It’s helpful to have a checklist of what they need to have in the home in order to administer [treatments] safely. In the beginning, [we provide] written instructions in plain language [explaining] methods for dissolving and discarding the medication. [We provide] things that supplement the in-person education that we are doing.

What are some considerations for selecting the liquid formulation of imatinib?

I was very excited to learn about the approval of [the liquid formulation] of imatinib. In my role, for as long as I’ve been doing it, I have educated patients and their families on either dissolving imatinib for use or helping them find a compounding pharmacy that could make the extemporaneously compounded oral suspension. It’s always going to be the preference of the team to use a dosage form that is easiest for patients and families to administer. For pediatric patients or those who are unable to swallow [pills], it will usually be the commercially available liquid formulation.

A potential barrier [to access of the liquid formulation] could be insurance coverage, as well as the time it may take to get all of the necessary approvals and getting them filled through a specialty pharmacy. Oftentimes, it may be urgent for patients to start this therapy. [We may need to] consider first starting the patient with dissolving tablets or compounded a suspension while we are working to obtain the [liquid] formulation.

It's great that it is available to patients because they’re on the therapy for a long time. It makes dose modifications easier, and [allows us] to administer it directly to the patients in a formulation that’s easy to give.

Are there any toxicities that are unique to liquid formulations?

In general, the liquid formulations have the same general AE profile [as other forms], but a key consideration with liquid formulations is volume. For our younger patients, or even our young adult patients with dysphagia, larger volumes can oftentimes be difficult to tolerate. Another concern is palatability and taste. For any liquid formulations that have a larger volume or don’t taste good, I worry about it potentially causing nausea, or there being any type of aversion that could lead to poor adherence.

Shorla Oncology announces FDA approval of Imkeldi (imatinib) oral solution, an oral liquid for the treatment of certain forms of leukemia and other cancers. News release. Shorla Oncology. November 25, 2024. Accessed June 18, 2025. https://www.businesswire.com/news/home/20241125044117/en

Imkeldi. Prescribing information. Shorla Oncology; 2001. Accessed June 18, 2025. https://shorlaoncology.com/pdf/Imkeldi_PrescribingInformation.pdf

Articles

The FDA's approval of a liquid formulation of imatinib addresses significant challenges faced by pediatric cancer patients and those with dysphagia. This development simplifies administration, enhances patient quality of life, and ensures reliable therapy delivery. Clinical pharmacists play a crucial role in managing oral chemotherapy, providing education, and supporting families in medication administration. Challenges include compounding medications and ensuring safe home administration. The liquid formulation offers ease of use, though insurance coverage and palatability remain concerns. Overall, this advancement represents a significant improvement in patient care and treatment adherence.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses how liquid formulations of oral agents, including imatinib, can aid in the delivery of anticancer agents.

Liquid Formulations Boost Treatment Adherence in Pediatric Patients With Cancer and Patients With Dysphagia

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphasia

“The biggest challenge with administering treatments to patients who have difficulty swallowing, whether [they are] a very young patient who hasn’t learned how to swallow pills or capsules or even our young adult patients with dysphasia, is whether these medications that the patients need are available in a liquid formulation.”

Kate Gasparini, PharmD, BCOP, BCPPS, a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center, discussed potential issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

One of the primary challenges in administering oral treatments in patients with cancer who have trouble swallowing, whether they are pediatric or have dysphagia, is the availability of a liquid formulation of a given drug, Gasparini began. Some medications can be compounded into a liquid formulation, dissolved, or manipulated by the patient or their caregiver so that they can be given, she continued. Although some medications have predetermined instructions on how to compound or dissolve them, oftentimes these processes require research on how to do this safely, she added.

Other barriers to giving oral therapies include identifying a pharmacy that can perform compounding near where patients live, Gasparini said. There are also instances in which there are no available compounding recipes, she noted.

Moreover, safely compounding agents at home often requires a lot of education and supplies for the patient’s families or caregivers, which can often be cumbersome, she said. Patients’ parents and/or caregivers may also be worried about correctly performing this process and about making errors, Gasparini added.

These barriers to treatment underscore the need for formulations that can be orally administered in a safe manner. 

In November 2024, the FDA approved an oral solution of imatinib (Imkeldi)

 for the treatment of patients with certain forms of leukemia and other types of cancer. The regulatory decision included indications in pediatric patients with newly diagnosed Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia in combination with chemotherapy as well as adult and pediatric patients with Ph-positive chronic myeloid leukemia in chronic phase. The flavored solution offers patients a therapeutic option that can be administered precisely in order to improve treatment adherence and accessibility.

Videos

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York.

In our exclusive interview, Gasparini discussed her role as a clinical pharmacy specialist in pediatric oncology, emphasizing her work in patient care, medication reviews, and supportive care. She also noted challenges in administering treatments to patients with dysphagia and emphasized the need for liquid formulations of common therapies. She explained the significance of the availability of the liquid formulation of imatinib, sharing its benefits for patients who struggle with swallowing. Gasparini also addressed potential barriers to accessing this medication, such as insurance coverage limitations, as well as the importance of considering the volume and palatability of liquid formulations to avoid adverse effects and ensure treatment adherence.

That’s all we have for today! Thank you for listening to this episode of 

supported by Shorla Oncology. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Kate Gasparini, PharmD, BCOP, BCPPS, discusses the oral formulation of imatinib for pediatric and adult patients with leukemias and other malignancies.

Addressing Treatment Adherence With Liquid Drug Formulations in CML and ALL | Supplements and Featured Publications

Liquid Formulations Boost Treatment Adherence in Pediatric Patients With Cancer and Patients With Dysphagia

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS